Surreal illustration of a child's face with a neural network formed by stars, symbolizing neuroblastoma research.

Unlocking Neuroblastoma: How a Gene Discovery Could Change Everything

Elliot Brynn monogram
Elliot Brynn in Health & Wellness November 2026 • 5 min read.

"Groundbreaking research identifies NKAIN2 as a potential key in understanding and treating this childhood cancer, offering new hope for families."


Neuroblastoma (NB), a cancer that develops from immature nerve cells, primarily affects young children. While most cases occur sporadically, a small percentage are familial, sparking a quest to identify the genes that predispose individuals to this disease. Researchers have already linked genes like ALK and PHOX2B to familial NB, yet these genes don't fully explain why some individuals develop the cancer while others don't, suggesting that additional genetic factors are at play.

A recent study has shed light on a previously unappreciated gene, NKAIN2 (Na/K transporting ATPase interacting 2), as a potential contributor to neuroblastoma development. The study, published in PLOS ONE, details how high-resolution array Comparative Genomic Hybridization (CGH) profiling led to the identification of NKAIN2 as a predisposing candidate gene. This discovery could refine our understanding of NB and pave the way for novel diagnostic and therapeutic strategies.

The researchers focused on an Italian family with a history of neuroblastoma, where multiple members were affected by the disease. By analyzing the genetic makeup of these individuals, they uncovered a specific genetic alteration involving the NKAIN2 gene, prompting further investigation into its role in neuroblastoma.

AI Search Multiple angles on this topic

Measuring Neuroblastoma’s Burden

A U.S. analysis characterizes neuroblastoma incidence and 5-year survival among children and adolescents, stratified by demographic and clinical factors, using data from United States Cancer Statistics and the National Program of Cancer Registries. A separate study analyzes global, regional, and national trends in paediatric neuroblastoma incidence and mortality from 1990 to 2021 using estimated annual percentage changes. The supplied source descriptions do not provide specific incidence, survival, or mortality estimates.

Biopsy and Risk Classification

For neuroblastoma, biopsy of the primary tumor or a metastatic soft-tissue lesion is typically essential for confirmation. The cited review describes biopsy as the gold standard for definitive diagnosis because it enables histological and genetic analysis, which are crucial for risk stratification. This makes obtaining suitable tissue central to diagnosis and classification; the source does not detail procedural limitations or alternatives.

Decoding NKAIN2: What the Research Reveals About Neuroblastoma

Surreal illustration of a child's face with a neural network formed by stars, symbolizing neuroblastoma research.

The study began with an Italian family affected by neuroblastoma. Three members, two siblings and a first cousin, all carried a germline mutation in the ALK gene, known to increase susceptibility to neuroblastoma. Interestingly, this mutation was inherited from their mothers, who did not have the disease. This observation underscored the need for additional genetic factors to trigger tumor development.

To identify these factors, the researchers conducted a high-resolution array CGH analysis, a technique that detects copy number variations (CNVs) in DNA. By comparing the DNA of affected siblings, they discovered a germline gain at the NKAIN2 locus in one sibling. This gain, meaning an extra copy of the gene, was inherited from a parent without the ALK mutation. This was unexpected, and suggested NKAIN2 might be important.

  • Germline Gain: One sibling showed a germline gain at the NKAIN2 locus, inherited from a parent without the ALK mutation.
  • NKAIN2 Expression: Surprisingly, the sibling without the genomic gain also showed high NKAIN2 expression, suggesting other regulatory mechanisms.
  • MYCN Amplification: High levels of NKAIN2 were found in MYCN-amplified NB cell lines, known for aggressive behavior.
  • Differentiation: NKAIN2 expression decreased during all-trans retinoic acid (ATRA) differentiation in NB cell lines.
AI Search Multiple angles on this topic

Genomic Clues and NKAIN2

Research on focal DNA copy number changes has highlighted alterations targeting ALK and NF1, as well as genes implicated in neuritogenesis, as potentially important in neuroblastoma pathogenesis. A separate report describes scientists identifying NKAIN2 through high-resolution array Comparative Genomic Hybridization profiling and presents it as a previously unconsidered gene that may be involved in neuroblastoma development. The supplied descriptions do not establish that NKAIN2 causes the disease or that it is already a therapeutic target.

Classification and Long-Term Challenges

The International Neuroblastoma Risk Group classification system, published in 2009, established consensus risk factors and a pretreatment risk grouping system based on survival and potential risk factors from 8,800 patients in the INRG database. Yet challenges extend beyond initial classification: a review of survivors describes late mortality, reduced quality of life, hearing impairment, thyroid disorders, cardiotoxicity, second malignancies, and altered musculoskeletal health. These sources describe both the scale of the classification effort and health problems that can persist after treatment.

The researchers then looked at how the NKAIN2 gene was expressed. Surprisingly, both affected siblings had high levels of NKAIN2, even the one without the extra copy of the gene. This meant there was something else turning on the NKAIN2 gene. Further, high levels of NKAIN2 were also found in neuroblastoma cell lines that are known to be aggressive, particularly those with MYCN amplification, a well-known driver of neuroblastoma. Finally, when neuroblastoma cells were treated with retinoic acid to make them more mature (differentiated), NKAIN2 levels decreased. These findings all pointed to a potential role for NKAIN2 in neuroblastoma development.

What Does This Mean for the Future of Neuroblastoma?

The identification of NKAIN2 as a potential player in neuroblastoma opens new avenues for research. Further studies are needed to fully understand its role and how it interacts with other genes and pathways involved in the disease. However, this discovery could eventually lead to the development of new diagnostic tools to identify individuals at higher risk of developing neuroblastoma, as well as targeted therapies that specifically address the role of NKAIN2 in tumor growth and differentiation, offering a more effective and less toxic approach to treating this devastating childhood cancer.

AI Search Multiple angles on this topic

NKAIN2 as a Research Lead

The cited report says scientists have pinpointed NKAIN2, a gene that could play a significant role in neuroblastoma, a childhood cancer. It presents the discovery as opening new avenues for understanding the disease and developing targeted therapies. The source describes a possibility for future work, not evidence that an NKAIN2-targeted treatment has been developed or shown to improve outcomes.

What the NKAIN2 signal means

A gene-copy gain and high gene expression are different observations: the sibling without the gain also had high NKAIN2 expression. The gain alone therefore cannot account for all the expression reported in this family.[1]

The findings place NKAIN2 among possible contributors to neuroblastoma growth and differentiation, but they do not establish that it causes the disease. The observations come from a family and do not show that the same pattern explains neuroblastoma more broadly.[1] [2]

How NKAIN2 fits with genetic predisposition

The family carried an activating ALK mutation inherited from unaffected mothers, yet not every carrier developed a tumor. That pattern supports the possibility that additional genetic factors are involved, rather than showing that the ALK mutation alone determines who develops neuroblastoma.[1] [2]

A separate account notes that PHOX2B mutations occur in only a subset of familial cases, consistent with a wider search for inherited contributors. This is a comparison of possible predisposition genes, not evidence that NKAIN2 has the same established role as PHOX2B.[3]

Other genetic findings also support the possibility of rare inherited contributions: loss-of-function BARD1 variants were reported in the context of a susceptibility locus. This broadens the genetic context but does not connect BARD1 directly to the NKAIN2 observations.[4]

PHOX2B mutations were reported in some individuals with presumed genetic predisposition, in some neuroblastoma-derived cell lines, and in none of the cited sporadic primary tumors. These groups differ, so the results provide context for where mutations were observed rather than a direct comparison of risk across groups.[5]

Separate clinical reports describe responses to lorlatinib in ALK-driven neuroblastoma and resistance mutations in patients with relapsed or refractory disease. They concern ALK-directed treatment, not NKAIN2, and do not show that NKAIN2 is a treatment target.[6] [7]

Terms for interpreting the genetic findings

Germline gain
An inherited gain in DNA copy number at a gene locus.[1]
Regulatory mechanisms
Processes that affect gene expression beyond the presence of a genomic gain.[1]

Sources

  1. High-Resolution Array CGH Profiling Identifies Na/K Transporting ATPase Interacting 2 (NKAIN2) as a Predisposing Candidate Gene in Neuroblastoma (pmc.ncbi.nlm.nih.gov)
  2. High-resolution array CGH profiling identifies Na/K transporting ATPase interacting 2 (NKAIN2) as a predisposing candidate gene in neuroblastoma. (pubmed.ncbi.nlm.nih.gov)
  3. Genetic Predisposition to Neuroblastoma (pmc.ncbi.nlm.nih.gov)
  4. The genetic landscape of high-risk neuroblastoma (pmc.ncbi.nlm.nih.gov)
  5. Prevalence and functional consequence of PHOX2B mutations in neuroblastoma. (pubmed.ncbi.nlm.nih.gov)
  6. Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results (pmc.ncbi.nlm.nih.gov)
  7. Circulating tumor DNA reveals mechanisms of lorlatinib resistance in patients with relapsed/refractory ALK-driven neuroblastoma (pmc.ncbi.nlm.nih.gov)

About this Article -

Written with AI assistance from published research, and reviewed by the Mystum team. See our About page for more information.

Everything You Need To Know

1

What exactly is neuroblastoma?

Neuroblastoma (NB) is a cancer that originates from immature nerve cells, predominantly affecting young children. The causes can be sporadic or, in a smaller number of cases, familial. Research has identified genes like ALK and PHOX2B associated with familial NB, but these don't fully explain the development of the cancer. The recent research highlights NKAIN2 as another potential factor, potentially leading to new diagnostic and therapeutic strategies.

2

Why is the discovery of NKAIN2's role in neuroblastoma considered important?

The discovery of NKAIN2's role is significant because it provides a new target for understanding and potentially treating neuroblastoma. The research suggests that NKAIN2 may contribute to tumor growth and differentiation. Understanding its function could lead to new diagnostic tools for identifying high-risk individuals and to the development of targeted therapies that specifically address NKAIN2's role in the disease, potentially providing more effective and less toxic treatments.

3

What is Array Comparative Genomic Hybridization (CGH), and how was it used in this research?

Array Comparative Genomic Hybridization (CGH) is a technique used to detect copy number variations (CNVs) in DNA. In this context, it was used to compare the DNA of siblings affected by neuroblastoma to identify genetic differences that might contribute to the disease. The researchers used high-resolution array CGH profiling to identify NKAIN2 as a predisposing candidate gene. This method allowed them to uncover a germline gain at the NKAIN2 locus in one sibling, indicating an extra copy of the gene.

4

What is MYCN amplification, and what does it have to do with NKAIN2?

MYCN amplification refers to an increase in the number of copies of the MYCN gene in neuroblastoma cells. MYCN is a well-known driver of neuroblastoma, and its amplification is associated with aggressive tumor behavior. The research found that high levels of NKAIN2 were present in neuroblastoma cell lines with MYCN amplification, suggesting a connection between NKAIN2 and aggressive neuroblastoma development. This connection implies that NKAIN2 may play a role in the pathways that drive tumor growth in MYCN-amplified neuroblastoma.

5

What is all-trans retinoic acid (ATRA) differentiation, and how does it relate to NKAIN2?

All-trans retinoic acid (ATRA) differentiation is a treatment approach used to make neuroblastoma cells more mature or differentiated. The study found that when neuroblastoma cells were treated with ATRA, the levels of NKAIN2 decreased. This suggests that NKAIN2 expression is linked to the immature state of neuroblastoma cells and that reducing NKAIN2 levels may contribute to the differentiation process. This finding is important because differentiation therapy aims to slow or stop cancer growth by promoting the maturation of cancer cells.

Newsletter Subscribe

Subscribe to get the latest articles and insights directly in your inbox.